-
Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs
•
Biocytogen (HKG: 2315), a leading biopharmaceutical company based in China, has announced a strategic research collaboration and licensing agreement with the Netherlands-based SOTIO Biotech B.V. The partnership grants SOTIO an exclusive option to license multiple fully human bispecific antibodies generated through Biocytogen’s proprietary RenLite platform. These antibodies will be utilized…
